Conexiant’s news site is now MDSpire News. Learn more
Advertisement
FDA adds generic valganciclovir oral solution
The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.
The article examines the objective, findings, and clinical context described in FDA adds generic valganciclovir oral solution.
Approach:
Approval: FDA granted final approval to Alembic Pharmaceuticals’ ANDA for valganciclovir oral solution, 50 mg/mL, therapeutically equivalent to Valcyte for Oral Solution.
Indications: Valganciclovir is indicated for CMV retinitis treatment in adults with AIDS and CMV disease prevention in high-risk kidney, heart, and kidney-pancreas transplant recipients. Reference-product labeling also includes prophylaxis in specified pediatric kidney and…
Administration and monitoring: The solution must be prepared by a pharmacist and taken with food. Labeling recommends monitoring blood counts and renal function; dosing adjustments are required for renal impairment.
Key Findings:
The approval was granted through the ANDA pathway, which establishes therapeutic equivalence to an approved reference product.
Alembic reported no new clinical efficacy or safety findings with the announcement.
Valganciclovir carries boxed warnings for hematologic toxicity, impaired fertility, fetal toxicity, mutagenesis, and carcinogenesis; clinically significant adverse effects include neutropenia, anemia, and thrombocytopenia.
Interpretation:
The approval adds a generic oral-solution product therapeutically equivalent to the reference product; the announcement did not report new clinical trial findings.
Limitations:
The announcement provided no new clinical efficacy or safety data.
